Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | ASPH | Q12797 | 1/20 | 0.30 |
| ▸ | CFTR | P13569 | 1/20 | 0.30 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13253377 | 0.85 | HSP90AA1 (0.36) | KIF11HSP90AA1 | |
| SCHEMBL24177969 | 0.84 | POLB (0.39) | POLBPKMPOLQAGBL2CFTR | |
| SCHEMBL20457471 | 0.80 | ALDH1A1 (0.34) | POLBASPH | |
| SCHEMBL16852159 | 0.80 | AGBL2 (0.34) | POLBPKMPOLQAGBL2KIF11 | |
| SCHEMBL19117728 | 0.79 | AGBL2 (0.40) | POLBPKMAGBL2KIF11 | |
| SCHEMBL14019047 | 0.78 | L3MBTL1 (0.42) | — | |
| SCHEMBL10197339 | 0.78 | HSP90AA1 (0.36) | POLBPKMPOLQAGBL2HSP90AA1 | |
| SCHEMBL10201441 | 0.78 | MAP3K12 (0.42) | HSP90AA1 | |
| SCHEMBL19370437 | 0.78 | PIK3CD (0.46) | POLBPKMPOLQ | |
| SCHEMBL8580894 | 0.76 | POLB (0.41) | POLBAGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334893-A1 | Isoxazole Analogs as FXR Agonists and Methods of Use Thereof | FXR1, SLC10A1, NR1H4 | POLB 3561/4885PKM 1862/4885POLQ 3916/4885 |
| US-20190194216-A1 | ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, GPBAR1 | POLB 3989/4885PKM 1704/4885POLQ 4361/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | POLB 3989/4885PKM 1704/4885POLQ 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.